BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31533938)

  • 1. Immune Profiles of Tumor Microenvironment and Clinical Prognosis among Women with Triple-Negative Breast Cancer.
    Deng L; Lu D; Bai Y; Wang Y; Bu H; Zheng H
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):1977-1985. PubMed ID: 31533938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes.
    DiNome ML; Orozco JIJ; Matsuba C; Manughian-Peter AO; Ensenyat-Mendez M; Chang SC; Jalas JR; Salomon MP; Marzese DM
    Ann Surg Oncol; 2019 Oct; 26(10):3344-3353. PubMed ID: 31342401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
    Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
    Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological and immunohistochemical characteristics of breast cancer patients from Northeast India with special reference to triple negative breast cancer: A prospective study.
    Sultana R; Kataki AC; Barthakur BB; Sarma A; Bose S
    Curr Probl Cancer; 2020 Oct; 44(5):100556. PubMed ID: 32044043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
    Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
    BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-34 contributes to poor prognosis in triple-negative breast cancer.
    Kajihara N; Kitagawa F; Kobayashi T; Wada H; Otsuka R; Seino KI
    Breast Cancer; 2020 Nov; 27(6):1198-1204. PubMed ID: 32578004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer.
    Bai F; Zhang P; Fu Y; Chen H; Zhang M; Huang Q; Li D; Li B; Wu K
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32300050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice.
    Losurdo A; De Sanctis R; Fernandes B; Torrisi R; Masci G; Agostinetto E; Gatzemeier W; Errico V; Testori A; Tinterri C; Roncalli M; Santoro A
    Sci Rep; 2020 Nov; 10(1):20100. PubMed ID: 33208857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer.
    Ginter PS; McIntire PJ; Cui X; Irshaid L; Liu Y; Chen Z; Shin SJ
    Clin Breast Cancer; 2017 Nov; 17(7):544-549. PubMed ID: 28410844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
    BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
    Mills MN; Yang GQ; Oliver DE; Liveringhouse CL; Ahmed KA; Orman AG; Laronga C; Hoover SJ; Khakpour N; Costa RLB; Diaz R
    Eur J Cancer; 2018 Jul; 98():48-58. PubMed ID: 29870876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
    Wu W; Wu M; Peng G; Shi D; Zhang J
    Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer.
    Sato K; Miura K; Tamori S; Akimoto K
    Cancer Genomics Proteomics; 2024; 21(3):316-326. PubMed ID: 38670590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
    Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
    Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
    O'Meara T; Safonov A; Casadevall D; Qing T; Silber A; Killelea B; Hatzis C; Pusztai L
    Breast Cancer Res Treat; 2019 May; 175(1):247-259. PubMed ID: 30725384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
    Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hot Spot and Whole-Tumor Enumeration of CD8
    McIntire PJ; Irshaid L; Liu Y; Chen Z; Menken F; Nowak E; Shin SJ; Ginter PS
    Clin Breast Cancer; 2018 Dec; 18(6):451-458.e1. PubMed ID: 29866579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implications of Transcriptomic Changes After Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Orozco JIJ; Grumley JG; Matsuba C; Manughian-Peter AO; Chang SC; Chang G; Gago FE; Salomon MP; Marzese DM
    Ann Surg Oncol; 2019 Oct; 26(10):3185-3193. PubMed ID: 31342395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
    Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
    Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.